Barbara Seliger

22.8k total citations · 3 hit papers
362 papers, 15.2k citations indexed

About

Barbara Seliger is a scholar working on Immunology, Oncology and Molecular Biology. According to data from OpenAlex, Barbara Seliger has authored 362 papers receiving a total of 15.2k indexed citations (citations by other indexed papers that have themselves been cited), including 234 papers in Immunology, 146 papers in Oncology and 126 papers in Molecular Biology. Recurrent topics in Barbara Seliger's work include Immunotherapy and Immune Responses (145 papers), Immune Cell Function and Interaction (134 papers) and Cancer Immunotherapy and Biomarkers (78 papers). Barbara Seliger is often cited by papers focused on Immunotherapy and Immune Responses (145 papers), Immune Cell Function and Interaction (134 papers) and Cancer Immunotherapy and Biomarkers (78 papers). Barbara Seliger collaborates with scholars based in Germany, United States and Sweden. Barbara Seliger's co-authors include Soldano Ferrone, Rudolf Lichtenfels, André Steven, Markus Maeurer, Rolf Kiessling, Francesco M. Marincola, Hinrich Abken, Ulrike Ritz, Ludger A. Wessjohann and Claudia Lennicke and has published in prestigious journals such as Proceedings of the National Academy of Sciences, Journal of Biological Chemistry and Circulation.

In The Last Decade

Barbara Seliger

351 papers receiving 14.9k citations

Hit Papers

align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Genes for epidermal growth factor receptor, transforming growth factor alpha, and epidermal growth factor and their expression in human gliomas in vivo.

1991 519 citations Barbara Seliger et al. profile →
Hydrogen peroxide – production, fate and role in redox signaling of tumor cells

2015 440 citations Rudolf Lichtenfels, Barbara Seliger et al. profile →
Cancer immunotherapy: Opportunities and challenges in the rapidly evolving clinical landscape

2017 434 citations Barbara Seliger, Francesco M. Marincola et al. profile →

Peers

Countries citing papers authored by Barbara Seliger

Since Specialization

Citations

This map shows the geographic impact of Barbara Seliger's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Barbara Seliger with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Barbara Seliger more than expected).

Fields of papers citing papers by Barbara Seliger

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Barbara Seliger. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Barbara Seliger. The network helps show where Barbara Seliger may publish in the future.

Co-authorship network of co-authors of Barbara Seliger

This figure shows the co-authorship network connecting the top 25 collaborators of Barbara Seliger. A scholar is included among the top collaborators of Barbara Seliger based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Barbara Seliger. Barbara Seliger is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	Association of immune evasion in myeloid sarcomas with disease manifestation and patients’ survival 2024 ·Frontiers in Immunology ·Marcus Bauer, (unknown), Hubert Hackl, (unknown), Nadja Jaekel, Hendrik Bläker, Haifa Kathrin Al‐Ali, Barbara Seliger, Claudia Wickenhauser	0
2	Immune modulatory microRNAs in tumors, their clinical relevance in diagnosis and therapy 2024 ·Journal for ImmunoTherapy of Cancer ·Christoforos Vaxevanis, Michael Bachmann, Barbara Seliger	10
3	Correlation of Increased Soluble Tumor Necrosis Factor Receptor 1 with Mortality and Dependence on Treatment in Non-Small-Cell Lung Cancer Patients: A Longitudinal Cohort Study 2024 ·Cancers ·(unknown), (unknown), Frank Bernhard Kraus, C. Ostheimer, Dirk Vordermark, Rafael Mikolajczyk, Barbara Seliger, Daniel Medenwald	0
4	Deciphering the role of alternative splicing in neoplastic diseases for immune-oncological therapies 2024 ·Frontiers in Immunology ·Marcus Bauer, (unknown), Claudia Wickenhauser, Barbara Seliger, (unknown)	2
5	Blood Immune Cells as Biomarkers in Long-Term Surviving Patients with Advanced Non-Small-Cell Lung Cancer Undergoing a Combined Immune/Chemotherapy 2023 ·Cancers ·(unknown), Wolfgang Schütte, (unknown), Barbara Seliger, Dagmar Riemann	1
6	Interferons and Resistance Mechanisms in Tumors and Pathogen-Driven Diseases—Focus on the Major Histocompatibility Complex (MHC) Antigen Processing Pathway 2023 ·International Journal of Molecular Sciences ·Chiara Massa, Yuan Wang, Nico Marr, Barbara Seliger	14
7	BRAF and MEK inhibitor combinations induce potent molecular and immunological effects in NRAS‐mutant melanoma cells: Insights into mode of action and resistance mechanisms 2023 ·International Journal of Cancer ·(unknown), (unknown), Alexander Schulz, Alexander Arthur Wurm, (unknown), Mildred Sergon, Antje Tunger, Mathias Lesche, Rebekka Wehner, Anja Müller, (unknown), Heike Niessner, Andreas Dahl, Stefan Beissert, Marc Schmitz, Friedegund Meier, Barbara Seliger, Dana Westphal	5
8	Peripheral Blood Monocyte Abundance Predicts Outcomes in Patients with Breast Cancer 2022 ·Cancer Research Communications ·Margaret L. Axelrod, Yu Wang, Yaomin Xu, Xiaopeng Sun, Cosmin A. Bejan, Paula I. González-Ericsson, Sara Nunnery, (unknown), Joshua Donaldson, Ángel Guerrero‐Zotano, Chiara Massa, Barbara Seliger, Melinda E. Sanders, Ingrid A. Mayer, Justin M. Balko	5
9	Underlying mechanisms of evasion from NK cells as rationale for improvement of NK cell-based immunotherapies 2022 ·Frontiers in Immunology ·Barbara Seliger, Ulrike Koehl	27
10	Biglycan as a potential regulator of tumorgenicity and immunogenicity in K-RAS-transformed cells 2022 ·OncoImmunology ·(unknown), Chiara Massa, (unknown), André Steven, Daniel Bethmann, (unknown), Claudia Wickenhauser, Barbara Seliger	7
11	Expression, Regulation and Function of microRNA as Important Players in the Transition of MDS to Secondary AML and Their Cross Talk to RNA-Binding Proteins 2020 ·International Journal of Molecular Sciences ·Marcus Bauer, Christoforos Vaxevanis, (unknown), Haifa Kathrin Al‐Ali, Nadja Jaekel, Michael Bachmann, Claudia Wickenhauser, Barbara Seliger	20
12	Cumulative suppressive index as a predictor of relapse free survival and overall survival in Human Papilloma Virus‐negative oral squamous cell carcinomas with negative resection margins 2020 ·Head & Neck ·(unknown), Daniel Bethmann, Zipei Feng, Shu‐Ching Chang, Alexander Eckert, Carmen Ballesteros‐Merino, (unknown), Matthias Kappler, Carlo Bifulco, Claudia Wickenhauser, Barbara Seliger, Bernard A. Fox, R. Bryan Bell	6
13	T-cell Responses in the Microenvironment of Primary Renal Cell Carcinoma—Implications for Adoptive Cell Therapy 2018 ·Cancer Immunology Research ·Rikke Andersen, Marie Christine Wulff Westergaard, Julie Westerlin Kjeldsen, Anja Müller, Natasja Wulff Pedersen, Sine Reker Hadrup, Özcan Met, Barbara Seliger, Bjarne Kromann‐Andersen, Thomas Hasselager, Marco Donia, Inge Marie Svane	57
14	Colorectal Carcinogenesis: Connecting K-RAS–Induced Transformation and CREB Activity In Vitro and In Vivo 2015 ·Molecular Cancer Research ·André Steven, (unknown), Christian V. Recktenwald, Bernhard Hiebl, Claudia Wickenhauser, Chiara Massa, Barbara Seliger	23
15	HER-2/neu Mediates Oncogenic Transformation via Altered CREB Expression and Function 2013 ·Molecular Cancer Research ·André Steven, (unknown), Chiara Massa, Manuela Iezzi, Rossano Lattanzio, Alessia Lamolinara, Jürgen Bukur, Anja Müller, Bernhard Hiebl, Hans-Jürgen Holzhausen, Barbara Seliger	30
16	B7-H4 Expression in Human Melanoma: Its Association with Patients' Survival and Antitumor Immune Response 2011 ·Clinical Cancer Research ·Dagmar Quandt, Eckhard Fiedler, (unknown), Wolfgang Ch. Marsch, Barbara Seliger	112
17	Association of IFN-γ Signal Transduction Defects with Impaired HLA Class I Antigen Processing in Melanoma Cell Lines 2011 ·Clinical Cancer Research ·(unknown), Juergen Bukur, Soldano Ferrone, Graham Pawelec, Yingdong Zhao, Ena Wang, Francesco M. Marincola, Barbara Seliger	49
18	Common Cancer Biomarkers 2006 ·Cancer Research ·(unknown), Yingdong Zhao, (unknown), Ping Jin, Monica C. Panelli, Sonia Voiculescu, Susanna Mandruzzato, (unknown), Barbara Seliger, Ralph S. Freedman, Phil R. Taylor, Nan Hu, Paola Zanovello, Francesco M. Marincola, Ena Wang	84
19	Ontogeny and Oncogenesis Balance the Transcriptional Profile of Renal Cell Cancer 2004 ·Cancer Research ·Ena Wang, Rudolf Lichtenfels, Jürgen Bukur, (unknown), Monica C. Panelli, Barbara Seliger, Francesco M. Marincola	23
20	Cytotoxic T lymphocytes define multiple peptide isoforms derived from the melanoma-associated antigen MART-1/Melan-A 1999 ·International Journal of Cancer ·(unknown), (unknown), Julia Karbach, Frank Momburg, Chiara Castelli, Alexander Knuth, Barbara Seliger, Markus Maeurer	11

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact